HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD)

Clinical trials for HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) explained in plain language.

Never miss a new study

Get alerted when new HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) trials appear

Sign up with your email to follow new studies for HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New drug duo aims to hold back deadly pancreatic cancer

Disease control Ongoing

This study is testing whether combining two drugs, pembrolizumab and olaparib, can better control advanced pancreatic cancer that has spread. The treatment is for patients whose cancer has stopped growing or shrunk while on platinum-based chemotherapy. Researchers want to see if …

Matched conditions: HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD)

Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated Apr 01, 2026 14:41 UTC

HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD)

Get alerted when new HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) trials appear

New drug duo aims to hold back deadly pancreatic cancer